Abstract EGFRvIII, a tumor-specific in-frame deletion of exons 2-7 that generates a constitutively active EGFR mutant, drives potent oncogenic signaling in a molecularly defined subset of glioblastoma (GBM) and is implicated in altered invasion, therapy resistance and immune modulation; because EGFRvIII occurs in a substantial fraction of GBMs we asked how suppression of this mutation in established tumors reshapes tumor cells and immune microenvironment in order to reveal treatment opportunities. We used an inducible EGFRvIII GBM mouse model to perform single-cell RNA sequencing and spatial transcriptomics on established with and without transcriptional suppression of EGFRvIII. Findings were validated in spatial transcriptomic profiles from human GBM specimens stratified by EGFR status. EGFRvIII suppression increases infiltration of myeloid and lymphoid cells into core tumor regions, slowing most tumor growth and increasing mouse survival. However, it also promotes invasion and proliferation in EGFRvIII-independent tumor-subpopulations, due to loss of EGFRvIII-driven communication between EGFRvIII-positive and -negative subpopulations. These observations are consistent with prior literature knowledge that direct EGFR inhibition often leads to resistance by vIII-negative populations, and complements it with insights into its mechanistic bases. Overall, our data argue for approaches that exploit the immune microenvironment changes to enhance direct EGFRvIII-targeted strategies for vIII-positive GBM. Citation Format: Fabio de Mello, David Eisenbarth, Feng Guo, Yamei Chen, Kun Huang, Chunhai Hao, Y. Alan Wang. Spatial transcriptomics unveils tumor microenvironment changes in murine glioblastoma upon EGFRvIII suppression abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7435.
Mello et al. (2026) studied this question.